Clinical Updates – Page 10

Advancing Noninvasive Imaging in Assessing Hemodynamic Significance of Right Coronary Artery Anomalies

By MedXY 09/27/2025

This article reviews a prospective study evaluating noninvasive anatomical and functional imaging methods to determine hemodynamic significance in right anomalous aortic origin of a coronary artery (R-AAOCA), proposing a stepwise diagnostic approach to reduce invasive testing.

Cardiology Clinical Updates Neurology news

Electrophysiological Study Surpasses ECG in Predicting Life-Threatening Conduction Delays in Myotonic Dystrophy Type 1

By MedXY 09/27/2025

In patients with myotonic dystrophy type 1 (DM1), electrophysiological study (EPS) using the His-ventricular (HV) interval is superior to electrocardiogram (ECG) in predicting major bradyarrhythmic events, suggesting enhanced risk stratification with EPS-guided thresholds.

Cardiology Clinical Updates news

Rising Trends into Transcatheter Aortic Valve Reinterventions: Redo TAVR and Explant Procedures from 2012 to 2024

By MedXY 09/27/2025

This article reviews increasing volumes and incidence of transcatheter aortic valve replacement (TAVR) reinterventions, analyzing procedural trends of redo TAVR and TAVR explant over the past decade, emphasizing implications for clinical practice and future strategies.

Cardiology Clinical Updates news

Systolic Blood Pressure as a Key Modifier of Survival Benefit from Microaxial Flow Pump Therapy in Infarct-Related Cardiogenic Shock: Insights from the DanGer Shock Trial

By MedXY 09/27/2025

This post hoc analysis of the DanGer Shock trial reveals that low systolic blood pressure at treatment initiation markedly enhances survival benefit from microaxial flow pump support in infarct-related cardiogenic shock.

Clinical Updates Pediatrics Public Health

Permethrin-Treated Baby Wraps: A Novel Strategy to Prevent Malaria in Young Children

By MedXY 09/27/2025

A randomized controlled trial in Uganda demonstrates that permethrin-treated baby wraps significantly reduce clinical malaria incidence among infants, offering an innovative complement to bed nets for malaria prevention in sub-Saharan Africa.

Clinical Updates Hematology-Oncology news

Advancing Chronic Lymphocytic Leukemia Management: The Impact of Measurable Residual Disease-Guided Ibrutinib-Venetoclax Therapy

By MedXY 09/26/2025

Phase 3 trial data demonstrate that ibrutinib-venetoclax therapy achieves superior undetectable measurable residual disease rates and significantly prolonged progression-free survival compared with ibrutinib alone or FCR in chronic lymphocytic leukemia.

Cardiology Clinical Updates Internal Medicine news

Extended Apixaban Therapy Reduces Recurrent VTE Risk in Patients with Provoked Events and Enduring Risk Factors

By MedXY 09/26/2025

A randomized trial demonstrates that low-dose apixaban for 12 months significantly lowers symptomatic recurrent VTE risk after provoked events with enduring risk factors, with minimal major bleeding.

Clinical Updates Neurology news

Nexiguran Ziclumeran Gene Editing: A Pioneering Treatment for Hereditary ATTR with Polyneuropathy

By MedXY 09/26/2025

Nexiguran ziclumeran, an innovative CRISPR-Cas9 gene-editing therapy, demonstrates rapid, sustained suppression of transthyretin (TTR) in hereditary ATTR polyneuropathy patients, showing promising late-phase clinical safety and efficacy.

Clinical Updates General Surgery Neurology news Specialties

Minimally Invasive Surgery versus Medical Management for Supratentorial Intracerebral Hemorrhage: Insights from the MIND Trial

By MedXY 09/26/2025

The MIND trial compared minimally invasive surgery using the Artemis device to standard medical management for supratentorial intracerebral hemorrhage, finding no significant improvement in 180-day functional outcomes or 30-day mortality with surgery.

Clinical Updates Diabetes & Endocrinology news

What’s New in the ADA 2024 Standards of Care: Practical Guidance on Weight‑Lowering Drugs, Cardiorenal Protection, and Technology for Diabetes

By MedXY 09/26/2025

The ADA 2024 Standards update care pathways for diabetes with stronger guidance on obesity pharmacotherapy (GLP‑1/GIP agents), earlier use of SGLT2/GLP‑1 for cardiorenal benefit, and expanded technology recommendations.

Clinical Updates Neurology news

Long-Term Safety and Effectiveness of Personalized Adaptive Deep Brain Stimulation in Parkinson’s Disease

By MedXY 09/26/2025

This international trial demonstrates that personalized adaptive deep brain stimulation (aDBS) is a safe, effective, and well-tolerated long-term therapy for Parkinson's disease patients previously stable on continuous DBS.

Clinical Updates Family Medicine & Nutrition news Specialties

Do Oily Fish Intake Increase Pancreatic Cancer Risk?

By MedXY 09/25/2025

This Mendelian randomization study reveals a surprising association between higher oily fish consumption and increased pancreatic cancer risk, highlighting new directions for dietary guidance and pancreatic disease prevention.

Clinical Updates news OB/GYN & Women's Health Oncology

Chemoradiotherapy Enhances Long-Term Survival in High-Risk Endometrial Cancer

By MedXY 09/25/2025

The PORTEC-3 trial demonstrates that adding platinum-based chemotherapy to pelvic radiotherapy significantly improves 10-year overall and recurrence-free survival in high-risk endometrial cancer, especially in patients with p53 abnormal tumors, emphasizing the importance of molecular profiling.

Clinical Updates Diabetes & Endocrinology Neurology news Specialties

Promising Links Between Diabetes Medications and Alzheimer’s Disease Risk Reduction

By MedXY 09/25/2025

Recent real-world data suggest GLP-1 receptor agonists and SGLT2 inhibitors may lower Alzheimer’s disease risk more effectively than DPP-4 inhibitors, highlighting the need for randomized trials to confirm potential neuroprotective benefits.

Clinical Updates Gastroenterology news

Decoding the Role of Reflux Secondary Bile Acids in Barrett’s Esophagus: Microbiome and Transcriptome Insights

By MedXY 09/25/2025

This study reveals that elevated reflux secondary bile acids in Barrett's esophagus influence the esophageal microbiome and gene expression, highlighting potential mechanisms underpinning progression to esophageal adenocarcinoma.

Clinical Updates news Pathology & Lab Medicine Public Health Specialties

Is Single-Test Tuberculosis Screening Adequate Before Initiating Biologic Therapy?

By MedXY 09/25/2025

A 20-year cohort study indicates that using QuantiFERON-TB Gold alone for TB screening before biologic therapy effectively reduces TB infection diagnoses and preventive treatments without increasing active TB risk, questioning the need for dual testing or routine retesting.

Clinical Updates news Oncology

Reevaluating the Role of Adjuvant Immunotherapy After Neoadjuvant Chemoimmunotherapy in Resectable Stage III NSCLC: Results from a Two-Center Real-World Study

By MedXY 09/25/2025

This study suggests adjuvant immunotherapy may not enhance survival after neoadjuvant chemoimmunotherapy and surgery in stage III NSCLC, with three cycles of neoadjuvant immunotherapy appearing optimal.

Clinical Updates news Oncology Specialties

Clarifying the Role of Repeat PSA Testing: Insights from the PLCO Cancer Screening Trial

By MedXY 09/25/2025

Annual PSA testing exhibits significant intra-individual variability; many elevated PSA levels normalize upon retesting, supporting guidelines recommending repeat testing before biopsy, with exceptions for patients with persistently elevated PSA.

Clinical Updates news

Personalized Low-Dose Aspirin Use for Cancer Prevention in Older Adults

By MedXY 09/25/2025

A secondary analysis of the ASPREE trial reveals low-dose aspirin’s heterogeneous effects on cancer prevention in older adults, highlighting clonal hematopoiesis of indeterminate potential (CHIP) as a key predictor for benefit.

Clinical Updates news Oncology Specialties

Is Lower-Dose Ribociclib Equally Effective in Hormone Receptor-Positive/ERBB2-Negative Breast Cancer?

By MedXY 09/25/2025

Lower-dose ribociclib (400 mg) does not demonstrate noninferior response rates compared to the standard 600 mg dose in advanced HR+/ERBB2- breast cancer but shows reduced toxicity and comparable progression-free survival, supporting 600 mg as the starting dose with dose reductions for adverse events.